• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Relay Therapeutics, Inc. (RLAY) Stock Price, News & Analysis

Relay Therapeutics, Inc. (RLAY) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.60

$0.32

(7.39%)

Day's range
$4.28
Day's range
$4.66
50-day range
$4.25
Day's range
$7.62
  • Country: US
  • ISIN: US75943R1023
52 wk range
$4.25
Day's range
$12.14
  • CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.24
  • Piotroski Score 2.00
  • Grade Outperform
  • Symbol (RLAY)
  • Company Relay Therapeutics, Inc.
  • Price $4.60
  • Changes Percentage (7.39%)
  • Change $0.32
  • Day Low $4.28
  • Day High $4.66
  • Year High $12.14

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $18.00
  • High Stock Price Target $20.00
  • Low Stock Price Target $16.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.63
  • Trailing P/E Ratio -3
  • Forward P/E Ratio -3
  • P/E Growth -3
  • Net Income $-341,973,000

Income Statement

Quarterly

Annual

Latest News of RLAY

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Relay Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of RLAY in the last quarter?

    In the last quarter Relay Therapeutics, Inc. earnings were on Wednesday, November, 6th. The Relay Therapeutics, Inc. maker reported -$0.63 EPS for the quarter, beating analysts' consensus estimates of -$0.77 by $0.14.

  • What is the Relay Therapeutics, Inc. stock price today?

    Today's price of Relay Therapeutics, Inc. is $4.60 — it has increased by +7.39% in the past 24 hours. Watch Relay Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Relay Therapeutics, Inc. release reports?

    Yes, you can track Relay Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Relay Therapeutics, Inc. stock forecast?

    Watch the Relay Therapeutics, Inc. chart and read a more detailed Relay Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Relay Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Relay Therapeutics, Inc. stock ticker.

  • How to buy Relay Therapeutics, Inc. stocks?

    Like other stocks, RLAY shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Relay Therapeutics, Inc.'s EBITDA?

    Relay Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Relay Therapeutics, Inc.’s financial statements.

  • What is the Relay Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -13.3865575824, which equates to approximately -1,338.66%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Relay Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Relay Therapeutics, Inc.'s financials relevant news, and technical analysis. Relay Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Relay Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Relay Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.